A5045763537- Cancer Genomics and Diagnostics
- Ubiquitin and proteasome pathways
- Peptidase Inhibition and Analysis
- RNA modifications and cancer
- BRCA gene mutations in cancer
- Cancer Cells and Metastasis
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Extracellular vesicles in disease
- Cancer, Hypoxia, and Metabolism
- Nuclear Structure and Function
- MicroRNA in disease regulation
- Histone Deacetylase Inhibitors Research
- PI3K/AKT/mTOR signaling in cancer
- Protein Degradation and Inhibitors
- DNA Repair Mechanisms
- Cancer-related Molecular Pathways
- Biochemical and Molecular Research
- Glycosylation and Glycoproteins Research
- Chemokine receptors and signaling
- Genomics and Chromatin Dynamics
- Cell Adhesion Molecules Research
Shenzhen Bay Laboratory
2025
Guangzhou Medical University
2021-2023
Peking University
2017-2020
Peking University Cancer Hospital
2017-2020
National Center for Nanoscience and Technology
2018
UCSF Helen Diller Family Comprehensive Cancer Center
2018
University of California, San Francisco
2018
Abstract Background Hepatocellular carcinoma (HCC) remains a medical challenge due to its high proliferation and metastasis. Although deubiquitinating enzymes (DUBs) play key role in regulating protein degradation, their pathological roles HCC have not been fully elucidated. Methods By using biomass spectrometry, co-immunoprecipitation, western blotting immunofluorescence assays, we identify ribosomal S16 (RPS16) as substrate of ubiquitin-specific peptidase 1 (USP1). The USP1-RPS16 axis the...
Abstract Androgen receptor splice variant 7 (AR-V7), a form of ligand-independent and constitutively activating androgen (AR), is considered as the key driver to initiate castration-resistant prostate cancer (CRPC). Because AR-V7 lacks ligand-binding domain, AR-targeted therapies that aim inactivate AR signaling through disrupting interaction between are limited in CRPC. Thus, emergence has become greatest challenge for treating Targeting protein degradation recently proposed novel avenue...
Abstract YTH domain family 2 (YTHDF2) is the first identified N6‐methyladenosine (m 6 A) reader that regulates status of mRNA. It has been reported overexpressed YTHDF2 promotes carcinogenesis; yet, its role in hepatocellular carcinoma (HCC) elusive. Herein, it demonstrated upregulated and can predict poor outcomes HCC. Decreased ubiquitination levels contribute to upregulation YTHDF2. Furthermore, heat shock protein 90 beta (HSP90β) STIP1 homology U‐box‐containing 1 (STUB1) physically...
BRAF mutations drive initiation and progression of various tumors. While inhibitors are effective in BRAF-mutant melanoma patients, intrinsic or acquired resistance to these therapies is common. Here, we identify non–receptor-type protein tyrosine phosphatase 23 (PTPN23) as an alternative target cancer cells. Silencing PTPN23 selectively kills cells but not those with wild-type BRAF. Mechanistically, PTPN23, a catalytically inactive phosphatase, intriguingly induces WNK3-mediated...
Abstract Blood‐based detection and molecular phenotyping are highly desired for the early diagnosis dynamic monitoring of cancer. Extracellular vesicles (EVs) carry information from cells origin biomarkers However, analysis EVs has been challenging due to their nanoscaled size. Here, an assessment serum based on microbead‐assisted flow cytometry is established. The clinical utility this method validated in human epidermal growth factor receptor 2 (HER2) breast Good correlation between status...
HER2 is a transmembrane receptor with intrinsic tyrosine kinase activity that overexpressed in almost 25% of human breast cancers. Here, we report the neddylation new post-translational modification controls its expression and oncogenic cancer. Two critical members pathway, NEDD8 NEDD8-activating enzyme E1 subunit 1 (NAE1), are detected specimens. Overexpressed NAE1 positively correlated Subsequent structure function experiments show directly interacts NAE1, whereas protein decreased by...
Abstract Objective: Triple-negative breast cancer (TNBC) is a heterogeneous disease with poor prognosis. Circulating tumor cells (CTCs) are promising predictor for prognoses but their reliability regarding progression-free survival (PFS) controversial. We aim to verify predictive value in TNBC. Methods: In present prospective cohort study, we used the Pep@MNPs method enumerate CTCs baseline blood samples from 75 patients TNBC (taken at inclusion this study) and analyzed correlations between...
<sec><b>Objective</b>To compare the efficacy of platinum- and non-platinum-based regimens as first-line treatment for advanced triple-negative breast cancer (TNBC) analyze relationship between their <i>BRCA</i> gene status.</sec><sec><b>Methods</b>Retrospectively clinical data 220 patients diagnosed pathologically with TNBC treated at Department Breast Oncology, Peking University Cancer Hospital from 2013 to 2018 evaluate chemotherapy. A total 114 had <i>BRCA1</i>/<i>2</i> tested by next...
Abstract Triple‐negative breast cancer (TNBC) accounts for 15–20% of all newly diagnosed cancers, and is enriched germline mutation BRCA . In Asian patients with cancer, 268 deleterious mutations BRCA1 242 BRCA2 have been identified so far, including a reported frameshift (rs80350973), apparently found only in people, low prevalence 0.3–1.7% different cohorts. Here, we the high (7.2%) rs80350973 among 125 Chinese TNBC, which implies its mutational predilection certain subtypes. Although had...
Abstract The translocation of biological macromolecules between cytoplasm and nucleus is great significance to maintain various life processes in both normal cancer cells. Disturbance transport function likely leads an unbalanced state tumor suppressors tumor-promoting factors. In this study, based on the unbiased analysis protein expression differences with a mass spectrometer human breast malignant tumors benign hyperplastic tissues, we identified that Importin-7, nuclear factor, highly...
More than 30% of estrogen receptor-positive breast cancers are resistant to primary hormone therapy, and about 40% that initially respond therapy eventually acquire resistance. Although the mechanisms resistance remain unclear, aberrant DNA methylation has been implicated in oncogenesis drug resistance.We investigated relationship between methylome variations circulating tumor exemestane resistance, track efficacy.We prospectively recruited 16 patients who were receiving first-line our...
Patients with HER2-positive metastatic breast cancer (MBC) benefit from trastuzumab-based therapy but eventually develop intrinsic or acquired resistance. Whether plasma HER2 gene copy number (GCN) could predict survival after trastuzumab treatment remained controversial. We evaluated the prognostic value of GCN using low-coverage whole-genome sequencing (LC-WGS).The was collected MBC patients whose pre-therapeutic samples were available before first-line treatment. Plasma DNA extracted and...
Extracellular vesicle-based diagnosis and molecular phenotyping provide great help for precise treatment of cancer. In article 1800122, Huiping Li, Ling Zhu, Yanlian Yang, co-workers establish an assessment the detection serum extracellular vesicles using microbead-assisted flow cytometry. Molecular is facilitated by immunostaining important biomarkers diagnosis, prognosis, therapeutic evaluation on nanosized that are enriched microsized aldehyde latex beads. This method shows efficacy in...
e13018 Background: Only a subset of patients with HER2 positive (HER2+) metastatic breast cancer (MBC) responds to anti-HER2 therapy. This study aimed at detecting plasma gene copy number (GCN) as prognostic factor in HER2+ MBC using next-generation sequencing (NGS). Methods: A total 50 were included this retrospective study, 44 HER2+, and six negative (HER2-) control. GCN either base line or after trastuzumab treatment was detected by NGS technique. Plasma ≤2.22, > 2.22-4.0 ≥4.0 predefined...
Background: Endocrine therapy resistance (ETR) is a great obstacle in the treatment of estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer. Patients with ETR have significantly decreased clinical benefit from endocrine (ET). Therefore, it quite important to find clinicopathological factors that affect outcome patients practice.Methods: We screened 405 consecutive ER+/HER2− metastatic cancer (MBC) who were treated 2013–2015 our hospital....
1105 Background: CTCs have emerged as an independent prognostic factor for metastatic breast cancer. However, the value of baseline regarding PFS in TNBC is still controversial, especially beyond first-line. We evaluated a novel combined NK cell/CTC detection system enumeration to better understand impact cell count on prognosis TNBC. Methods: 83 consecutive patients with were enrolled and received new line therapy (median=2, range: 1~5). Baseline circulating cells isolated enumerated...
1080 Background: Circulating DNA fragments (ctDNA) are using to longitudinal non-invasive molecular monitoring and resistance mechanism interrogation of the disease by detecting genomic alteration change clonal evolution including somatic mutation copy number alteration. Methods: We performed a retrospective analysis blood samples from mBC patients (pts) collected at pre-treatment, on-treatment, progression. A highly sensitive, plasma-derived ctDNA-based NGS assay was conducted detect...
Background: Endocrine therapy resistance (ETR) is a great obstacle in the treatment of estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2−) breast cancer. Patients with ETR have significantly decreased clinical benefit from endocrine (ET). Therefore, it quite important to find clinicopathological factors that affect outcome patients practice. Methods: We screened 405 consecutive ER+/HER2− metastatic cancer (MBC) who were treated 2013–2015 our hospital....
e24029 Background: In estrogen receptor-positive breast cancer patients (pts), more than 30% have primary hormone therapy (HT) resistance while the precise mechanism underlies remain unclear. Our study, for first time, focused on relationship between methylomes variation and exemestane (EXEr). Methods: All 16 pts received first-line based HT were prospectively recruited in our center. Blood samples of baseline, follow-up disease progression (PD) collected. Pts (4/16) who had PD within 6...
e12565 Background: Platinum-based therapy remains an effective treatment for triple-negative breast cancer (TNBC), however, the usage is largely limited due to its side effect and rapidly developed drug resistance. High prevalence of BRCA1/2 mutations are reported in TNBC. Here we explored efficacy platinum-based regimens as first-line Chinese patients (pts) with advanced TNBC, analyzed association germline (gBRCA). Methods: We retrospectively analyze 220 diagnosed TNBC who were treated at...